International Journal of Medical Investigation
Sun, Jan 5, 2025
Volume 12, Issue 4 (12-2023)
Int J Med Invest 2023, 12(4): 67-81 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Soltani D, Mohammadzadeh A, Hatami B. Neutrophil-To-Lymphocyte Ratio In Patients With COVID-19 Infection: A Narrative Review. Int J Med Invest 2023; 12 (4) :67-81
URL: http://intjmi.com/article-1-1089-en.html
URL: http://intjmi.com/article-1-1089-en.html
Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Abstract: (748 Views)
Coronavirus disease 2019 (COVID-19), a contagious illness, has been quickly spreading throughout the world and continues to pose a danger to public health on a worldwide scale. It is essential to diagnose potentially serious or critical patients immediately and provide targeted patients with prompt therapy because patients with critical or severe cases have poor prognoses. Current biomarkers cannot reliably predict the severity of COVID-19 infection; thus, we need surrogate indicators to determine the severity of COVID-19 and forecast its progression. The neutrophil-to-lymphocyte ratio (NLR) is a new biomarker that has been linked to inflammation and prognosis in a variety of diseases. In this narrative review, we investigated the NLR's diagnostic and prognostic validity in patients with COVID-19 infection.
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
